ReviewClinical medicine insights. Blood disorders2020
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.
Review in Clinical medicine insights. Blood disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia.Journal of clinical pharmacology · 2026Pooled it
- What Is Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog.Veterinary clinical pathology · 2026Article
- Review
- A practical tool for predicting outcomes in essential thrombocythemia: Triple A risk model and beyond.Blood advances · 2026Article
- The molecular management of classic myeloproliferative neoplasm.Journal of the Egyptian National Cancer Institute · 2025Review
- Essential Thrombocythemia's Role in the Complex Landscape of Vasculitis: A Case Report.Clinical case reports · 2025Article
- Non-ST-Elevation Myocardial Infarction as the Initial Manifestation of Calreticulin-Positive Essential Thrombocythemia: A Case Report.Journal of cardiovascular development and disease · 2025Article
- Management of Bleeding, Thrombotic and Pregnancy-Related Complications in Women with Myeloproliferative Neoplasms: A Case-Based Review Focusing on Sex-Specific Challenges.Journal of clinical medicine · 2025Review
- ST-Segment Elevation Myocardial Infarction With Acute Stent Thrombosis as the Initial Presentation of Essential Thrombocythemia.JACC. Case reports · 2025Article
- Coexistence of Essential Thrombocythemia and Waldenström Macroglobulinemia: A Case Report.Case reports in hematology · 2025Article
- Co-Existing Non-Occlusive Splenic Vein and Superior Mesenteric Vein Thrombosis in an Acute Necrotic Pancreatitis Patient-A Case Report.Clinical case reports · 2024Article
- Digital gangrene: can be the first manifestation of essential thrombocythemia? a case report.Annals of medicine and surgery (2012) · 2024Article
- Essential thrombocythemia: nutritional management in weight loss and malnutrition.The Pan African medical journal · 2024Article
- An Approach to the Investigation of Thrombocytosis: Differentiating between Essential Thrombocythemia and Secondary Thrombocytosis.Advances in hematology · 2024Article
- Case report: Peri-procedural hydroxyurea helps minimize bleeding in patients with Essential Thrombocythemia associated with acquired von Willebrand syndrome.Frontiers in oncology · 2024Article
- Molecular landscape of theBiomedical reports · 2023Article
- Co‑existence of triple‑negative essential thrombocythemia and double transcript chronic myeloid leukemia: A case report.Molecular and clinical oncology · 2023Article
- Spontaneous bacterial peritonitis complicating extensive splanchnic vein thrombosis, a rare manifestation of essential thrombocythemia: A case report.Clinical case reports · 2023Article
- Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study.Journal of thrombosis and thrombolysis · 2023Article
- In-Hospital Outcomes of Acute Myocardial Infarction With Essential Thrombocythemia and Polycythemia Vera: Insights From the National Inpatient Sample.Journal of the American Heart Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Essential Thrombocythemia is a Chronic Philadelphia-negative Myeloproliferative Neoplasm characterized by a survival curve that is only slightly worse than that of age- and sex-adjusted healthy population. The criteria for diagnosis were reviewed in 2016 by WHO. The incidence varies from 0.2 to 2.5:100 000 people per year, with a prevalence of 38 to 57 cases per 100 000 people. The main characteristics of ET are the marked thrombocytosis and the high frequency of thrombosis. The spectrum of symptoms is quite wide, but fatigue results to be the most frequent. Thrombosis is frequently observed, often occurring before or at the time of diagnosis. The classification of thrombotic risk has undergone several revisions. Recently, the revised-IPSET-t has distinguished 4 risk classes, from very low risk to high risk. Driver mutations seem to influence thrombotic risk and prognosis, while the role of sub-driver mutations still remains uncertain. Antiplatelet therapy is recommended in all patients aged ⩾ 60 years and in those with a positive history of thrombosis or with cardiovascular risk factors, while cytoreductive therapy with hydroxyurea or interferon is reserved for high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.